PMCCPMCCPMCC

Search tips
Search criteria 

Advanced

 
Logo of jpnSubmit a ManuscriptEmail AlertsAbout JPNJournal of Psychiatry and Neuroscience
 
J Psychiatry Neurosci. 1995 March; 20(2): 113–118.
PMCID: PMC1188670

The successful pharmacological treatment of adolescents and young adults with borderline personality disorder: a preliminary open trial of flupenthixol.

Abstract

Borderline personality disorder is a significantly disabling disturbance often arising in adolescents or young adults. In the absence of demonstrated effective treatments in this population, this open prospective study evaluated the effect of low dose (3 mg per day) flupenthixol in 13 rigorously diagnosed adolescents with borderline personality disorder. Therapeutic outcome over eight weeks of treatment assessed across measures of impulsivity, depression/dysphoria, general psychopathology and global functioning showed significant improvement in all spheres. These findings suggest that low dose flupenthixol may have a role to play in the short-term treatment of this population.

Full text

Full text is available as a scanned copy of the original print version. Get a printable copy (PDF file) of the complete article (1.0M), or click on a page image below to browse page by page. Links to PubMed are also available for Selected References.

Selected References

These references are in PubMed. This may not be the complete list of references from this article.
  • Akiskal HS, Hirschfeld RM, Yerevanian BI. The relationship of personality to affective disorders. Arch Gen Psychiatry. 1983 Jul;40(7):801–810. [PubMed]
  • Barnes RJ. Mesoridazine (Serentil) in personality disorders--a controlled trial in adolescent patients. Dis Nerv Syst. 1977 Apr;38(4):258–264. [PubMed]
  • BECK AT, WARD CH, MENDELSON M, MOCK J, ERBAUGH J. An inventory for measuring depression. Arch Gen Psychiatry. 1961 Jun;4:561–571. [PubMed]
  • Blackwood DH, St Clair DM, Kutcher SP. P300 event-related potential abnormalities in borderline personality disorder. Biol Psychiatry. 1986 May;21(5-6):560–564. [PubMed]
  • Brent DA, Zelenak JP, Bukstein O, Brown RV. Reliability and validity of the structured interview for personality disorders in adolescents. J Am Acad Child Adolesc Psychiatry. 1990 May;29(3):349–354. [PubMed]
  • Carney MW, Sheffield BF. Comparison of antipsychotic depot injections in the maintenance treatment of schizophrenia. Br J Psychiatry. 1976 Nov;129:476–481. [PubMed]
  • Carney MW, Sheffield BF. The long-term maintenance treatment of schizophrenic out-patients with depot flupenthixol. Curr Med Res Opin. 1973;1(7):423–426. [PubMed]
  • Coccaro EF, Siever LJ, Klar HM, Maurer G, Cochrane K, Cooper TB, Mohs RC, Davis KL. Serotonergic studies in patients with affective and personality disorders. Correlates with suicidal and impulsive aggressive behavior. Arch Gen Psychiatry. 1989 Jul;46(7):587–599. [PubMed]
  • Cole JO, Salomon M, Gunderson J, Sunderland P, 3rd, Simmonds P. Drug therapy in borderline patients. Compr Psychiatry. 1984 May-Jun;25(3):249–254. [PubMed]
  • Cowdry RW, Gardner DL. Pharmacotherapy of borderline personality disorder. Alprazolam, carbamazepine, trifluoperazine, and tranylcypromine. Arch Gen Psychiatry. 1988 Feb;45(2):111–119. [PubMed]
  • Derogatis LR, Lipman RS, Rickels K, Uhlenhuth EH, Covi L. The Hopkins Symptom Checklist (HSCL): a self-report symptom inventory. Behav Sci. 1974 Jan;19(1):1–15. [PubMed]
  • Dulit RA, Fyer MR, Haas GL, Sullivan T, Frances AJ. Substance use in borderline personality disorder. Am J Psychiatry. 1990 Aug;147(8):1002–1007. [PubMed]
  • Egan J. Treatment of borderline conditions in adolescents. J Clin Psychiatry. 1988 Sep;49 (Suppl):32–35. [PubMed]
  • Frolund F. Treatment of depression in general parctice: a controlled trial of flupenthixol ('Fluanxol'). Curr Med Res Opin. 1974;2(2):78–89. [PubMed]
  • Gardner DL, Cowdry RW. Pharmacotherapy of borderline personality disorder: a review. Psychopharmacol Bull. 1989;25(4):515–523. [PubMed]
  • Gawin FH, Allen D, Humblestone B. Outpatient treatment of 'crack' cocaine smoking with flupenthixol decanoate. A preliminary report. Arch Gen Psychiatry. 1989 Apr;46(4):322–325. [PubMed]
  • Goldberg SC, Schulz SC, Schulz PM, Resnick RJ, Hamer RM, Friedel RO. Borderline and schizotypal personality disorders treated with low-dose thiothixene vs placebo. Arch Gen Psychiatry. 1986 Jul;43(7):680–686. [PubMed]
  • Gruber AJ, Cole JO. Antidepressant effects of flupenthixol. Pharmacotherapy. 1991;11(6):450–459. [PubMed]
  • Gunderson JG, Kolb JE, Austin V. The diagnostic interview for borderline patients. Am J Psychiatry. 1981 Jul;138(7):896–903. [PubMed]
  • Gunderson JG, Phillips KA. A current view of the interface between borderline personality disorder and depression. Am J Psychiatry. 1991 Aug;148(8):967–975. [PubMed]
  • Hamilton BA, Jones PG, Hoda AN, Keane PM, Majid I, Zaidi SI. Flupenthixol and fluvoxamine in mild to moderate depression: a comparison in general practice. Pharmatherapeutica. 1989;5(5):292–297. [PubMed]
  • HAMILTON M. A rating scale for depression. J Neurol Neurosurg Psychiatry. 1960 Feb;23:56–62. [PMC free article] [PubMed]
  • Hyttel J, Larsen JJ, Christensen AV, Arnt J. Receptor-binding profiles of neuroleptics. Psychopharmacology Suppl. 1985;2:9–18. [PubMed]
  • Johnson DA. A double-blind comparison of flupenthixol, nortriptyline and diazepam in neurotic depression. Acta Psychiatr Scand. 1979 Jan;59(1):1–8. [PubMed]
  • Kong DS, Yeo SH. An open clinical trial with the long-acting neuroleptics flupenthixol decanoate and fluphenazine decanoate in the maintenance treatment of schizophrenia. Pharmatherapeutica. 1989;5(6):371–379. [PubMed]
  • Kutcher SP, Blackwood DH. Pharmacotherapy of the borderline patient: a critical review and clinical guidelines. Can J Psychiatry. 1989 May;34(4):347–353. [PubMed]
  • Kutcher SP, Blackwood DH, St Clair D, Gaskell DF, Muir WJ. Auditory P300 in borderline personality disorder and schizophrenia. Arch Gen Psychiatry. 1987 Jul;44(7):645–650. [PubMed]
  • Kutcher S, Boulos C, Ward B, Marton P, Simeon J, Ferguson HB, Szalai J, Katic M, Roberts N, Dubois C, et al. Response to desipramine treatment in adolescent depression: a fixed-dose, placebo-controlled trial. J Am Acad Child Adolesc Psychiatry. 1994 Jun;33(5):686–694. [PubMed]
  • Lahmeyer HW, Reynolds CF, 3rd, Kupfer DJ, King R. Biologic markers in borderline personality disorder: a review. J Clin Psychiatry. 1989 Jun;50(6):217–225. [PubMed]
  • Lane RD, Glazer WM, Hansen TE, Berman WH, Kramer SI. Assessment of tardive dyskinesia using the Abnormal Involuntary Movement Scale. J Nerv Ment Dis. 1985 Jun;173(6):353–357. [PubMed]
  • Leone NF. Response of borderline patients to loxapine and chlorpromazine. J Clin Psychiatry. 1982 Apr;43(4):148–150. [PubMed]
  • Links PS, Steiner M. Psychopharmacologic management of patients with borderline personality disorder. Can J Psychiatry. 1988 Jun;33(5):355–359. [PubMed]
  • Lucas PB, Gardner DL, Wolkowitz OM, Cowdry RW. Dysphoria associated with methylphenidate infusion in borderline personality disorder. Am J Psychiatry. 1987 Dec;144(12):1577–1579. [PubMed]
  • Marton P, Korenblum M, Kutcher S, Stein B, Kennedy B, Pakes J. Personality dysfunction in depressed adolescents. Can J Psychiatry. 1989 Nov;34(8):810–813. [PubMed]
  • McManus M, Lerner H, Robbins D, Barbour C. Assessment of borderline symptomatology in hospitalized adolescents. J Am Acad Child Psychiatry. 1984 Nov;23(6):685–694. [PubMed]
  • Merskey H. Some observations on low dose flupenthixol for affective illness. Can J Psychiatry. 1986 Jun;31(5):485–485. [PubMed]
  • Montgomery SA, Montgomery DB. The prevention of suicidal acts in high-risk patients. Adv Biochem Psychopharmacol. 1984;39:315–317. [PubMed]
  • Ovhed I. A double-blind study of flupenthixol ('Fluanxol') in general practice. Curr Med Res Opin. 1976;4(2):144–150. [PubMed]
  • Robertson MM, Trimble MR. Major tranquillisers used as antidepressants. A review. J Affect Disord. 1982 Sep;4(3):173–193. [PubMed]
  • Schulz SC, Schulz PM, Dommisse C, Hamer RM, Blackard WG, Narasimhachari N, Friedel RO. Amphetamine response in borderline patients. Psychiatry Res. 1985 Jun;15(2):97–108. [PubMed]
  • Serban G, Siegel S. Response of borderline and schizotypal patients to small doses of thiothixene and haloperidol. Am J Psychiatry. 1984 Nov;141(11):1455–1458. [PubMed]
  • Siever LJ, Trestman RL, Coccaro E, Amin F, Lawrence T, Gabriel S, Mitropoulou V. Monoamines in personality disorder. Clin Neuropharmacol. 1992;15 (Suppl 1 Pt A):231A–232A. [PubMed]
  • Soloff PH, George A, Nathan RS, Schulz PM, Ulrich RF, Perel JM. Progress in pharmacotherapy of borderline disorders. A double-blind study of amitriptyline, haloperidol, and placebo. Arch Gen Psychiatry. 1986 Jul;43(7):691–697. [PubMed]
  • Soloff PH, George A, Nathan RS, Schulz PM, Perel JM. Paradoxical effects of amitriptyline on borderline patients. Am J Psychiatry. 1986 Dec;143(12):1603–1605. [PubMed]
  • Tam W, Young JP, John G, Lader MH. A controlled comparison of flupenthixol decanoate injections and oral amitriptyline in depressed out-patients. Br J Psychiatry. 1982 Mar;140:287–291. [PubMed]
  • Träskman-Bendz L, Asberg M, Schalling D. Serotonergic function and suicidal behavior in personality disorders. Ann N Y Acad Sci. 1986;487:168–174. [PubMed]
  • Young JP, Hughes WC, Lader MH. A controlled comparison of flupenthixol and amitriptyline in depressed outpatients. Br Med J. 1976 May 8;1(6018):1116–1118. [PMC free article] [PubMed]

Articles from Journal of Psychiatry & Neuroscience : JPN are provided here courtesy of Canadian Medical Association